REG - Haleon PLC - Transactions in Own Shares

HALEONAnnouncement

01/06/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260601:nRSA3199Ga&default-theme=true

RNS Number : 3199G  Haleon PLC  01 June 2026

 

Haleon plc: Aggregated information - transactions in own shares

 

1 June 2026: Haleon plc (the "Company" or "Haleon") today announces the
purchase of 10,149,493 ordinary shares of £0.01 each in the Company (the
"Shares") for cancellation under its share buyback programme announced on 12
March 2026.

 

                                                    London Stock Exchange  CBOE (UK)/BXE  CBOE (UK)/CXE  Aquis
 Date of purchase:                                  26 May 2026
 Number of Shares purchased:                        905,222                768,112        786,713        -
 Highest price paid per Share (p):                  346.0000               346.0000       346.0000       -
 Lowest price paid per Share (p):                   341.6000               341.6000       341.6000       -
 Volume weighted average price paid per Share (p):  343.1415               343.1167       343.0473       -
 Date of purchase:                                  27 May 2026
 Number of Shares purchased:                        306,596                132,534        130,988        -
 Highest price paid per Share (p):                  344.0000               344.0000       344.0000       -
 Lowest price paid per Share (p):                   341.4000               341.4000       341.4000       -
 Volume weighted average price paid per Share (p):  343.0269               343.0300       343.0293       -
 Date of purchase:                                  28 May 2026
 Number of Shares purchased:                        1,744,909              939,106        936,881        -
 Highest price paid per Share (p):                  344.6000               344.4000       344.6000       -
 Lowest price paid per Share (p):                   340.8000               340.8000       340.8000       -
 Volume weighted average price paid per Share (p):  342.1974               342.1678       342.3110       -
 Date of purchase:                                  29 May 2026
 Number of Shares purchased:                        1,517,312              1,012,452      968,668        -
 Highest price paid per Share (p):                  342.2000               342.2000       342.2000       -
 Lowest price paid per Share (p):                   336.1000               336.1000       336.1000       -
 Volume weighted average price paid per Share (p):  338.5963               338.6275       338.5752       -

 

Following the settlement of the above, the Company's registered share capital
is 8,859,337,794 ordinary shares of £0.01 each, of which 12,076,964 are
held as treasury shares. Therefore, the number of ordinary shares with voting
rights is 8,847,260,830 and this figure may be used by shareholders to
determine if they are required to notify their interest, or a change to their
interest, in Haleon under the FCA's Disclosure Guidance and Transparency
Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it
applies in the UK (the Market Abuse Regulation), a full breakdown of the
individual trades is available at the link below:

 

http://www.rns-pdf.londonstockexchange.com/rns/3199G_1-2026-5-29.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/3199G_1-2026-5-29.pdf)

 

This announcement does not constitute, or form part of, an offer or any
solicitation of an offer for securities in any jurisdiction.

 

This announcement and individual trade breakdown will also be available on the
Company's website at: www.haleon.com/investors
(http://www.haleon.com/investors) .

 

 Enquiries

 Investors                                                                       Media

 Jo Russell                              +44 7787 392441                         Zoë Bird                             +44 7736 746167
 Rakesh Patel                            +44 7552 484646                         Victoria Durman                      +44 7894 505730
 Email: investor-relations@haleon.com (mailto:investor-relations@haleon.com)     Email: corporate.media@haleon.com (mailto:corporate.media@haleon.com)

 

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better
everyday health. Our people, our brands, our research, our investment and our
innovation are aimed at improving the everyday health of consumers. Our
product portfolio spans six major categories - Oral Health, Vitamins, Minerals
and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and
Therapeutic Skin Health and Other. Our superior brands - such as Advil,
Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and
Voltaren - are trusted by more than one billion consumers and are recommended
by health professionals around the world.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSBLGDUIXDDGLC



            Copyright 2019 Regulatory News Service, all rights reserved